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ABSTRACT 
 
Background: The role of surgery of lung metastases (LM) secondary to colorectal cancer remains 
controversial. The bulk of evidence derives from single surgical series, hampering any definitive conclusion. 
The aim of this study was to compare the outcome of colorectal cancer patients with LM submitted or not to 
surgery. 
 
Patients and Methods: Data about 409 patients with LM as first evidence of advanced disease were 
extracted from a database of 1411 patients. The patients were divided into three groups: G1 comprised 
patients (n=255) with pulmonary and extra-pulmonary metastases; G2 patients with LM only and not 
submitted to surgery (n=104); G3 patients with LM only and submitted to surgery (n=50). 
 
Results: No difference in response rates emerged between G1 and G2. Median PFS (95%CI) was: 10.3 (9.4-
11.2), 10.5 (9.6-11.4), and 26.2 (10.4-42.0) months for groups G1, G2, and G3, respectively. No difference 
in PFS was observed between G1 and G2, whereas there was a statistically significant difference between G2 
and G3. Median OS was 24.2 (21.5-26.9), 31.5 (28.8-34.2), and 72.4+ (40.7-104.1) months, respectively. 
Survival was longer in the resected patients: 17 survived for more than 5 years and 3 more than 10 years. In 
the patients with LM only and not submitted to surgery, 4 survived for 5 years and none longer than 10 
years.   
 
Conclusions: Even though patients with resectable LM are more likely to be those with a better outcome, 
our study provides evidence suggesting an active role of surgery in improving survival in this patient subset. 
INTRODUCTION 
The clinical outcome of patients with metastatic colorectal cancer (CRC) has improved, with an 
increase in median overall survival from 8-12 months in the 1990s to currently more than 20 
months, along with a not negligible proportion of patients still alive at 5 and 10 years. This 
improvement in treatment efficacy has been achieved mainly following the clinical use of highly 
active cytotoxic agents (e.g., irinotecan, oxaliplatin) and, more recently, of molecular targeted 
therapies (e.g.,cetuximab, panitumumab, and bevacizumab) (1) and through the multidisciplinary 
management of patients. Resection of liver metastases upfront or after neoadjuvant chemotherapy 
has been consistently demonstrated to prolong survival (2). 
At the time of advanced disease presentation, pulmonary CRC metastases are revealed in 
approximately 10-15% of the patients (3). The best estimate of isolated lung metastases (i.e. without 
localization in other organs) lie between 1.7% and 7.4% (4). The management of this latter 
subgroup of patients is a matter of debate. Surgical resection  is a widespread clinical practice. 
Several studies describing single institution series of resected patients reported 5-year survival rates 
between 21% and 61.4%, exceeding those normally associated with metastatic colorectal cancer (5-
7). This notable difference in 5-year survival rates within surgical studies reflects the quality of 
evidence for pulmonary metastasectomy that is insufficient to draw definitive conclusions (8). In 
fact, while some Authors demonstrated stage of the primary tumor, distribution of the metastases, 
disease free interval, CEA, gender, age, complete resection (R0), number of lung metastases, and 
vascular and lymphatic invasion to be variables influencing 5-year survival rate, others reported 
opposite findings (9). Moreover, inclusion criteria guidelines for lung metastasectomy published by 
several institutions lie on the experience of the single institution (10-12). Despite these 
discrepancies, the reported outcomes are widely held to corroborate the benefit gained from lung 
surgery when compared to historical series. To solve the debate, a phase III prospective randomized 
clinical trial designed to compare patients with lung metastases to be allocated to “active 
monitoring” or “active monitoring with pulmonary metastasectomy” has been advocated (13). 
To our knowledge, there is no study which compared the outcome in CRC patients with lung 
metastases, surgically resected or not, followed and treated at the same institutions and in the same 
timeframe. In this retrospective study we searched the databases of three institutions and extracted 
the data on patients consecutively followed and treated from the time of first appearance of 
metastatic disease. We then compared their outcomes  according to whether they were submitted or 
not to lung metastasectomy. 
 
 
 
PATIENTS AND METHODS 
 
Patients 
Clinical databases of three institutions (University of Torino, Oncology Unit, San Luigi di 
Orbassano Hospital; University of Torino [center 1]; Institute for Cancer Research and Treatment 
[IRCC] Candiolo [center 2]; and University of Eastern Piedmont, Maggiore della Carità Hospital, 
Novara [center 3]) were retrospectively investigated. In these databases the clinical characteristics 
and outcomes of all metastatic CRC patients followed and treated from the time of first diagnosis of 
metastatic disease have been recorded since 1993. The data from patients with pulmonary 
metastases diagnosed between January 1
st
 1994 and June 30
th
 2010 were then extracted and entered 
into a new database generated for the purpose of this study. The database included: patient 
demographics; primary tumor characteristics; prognostic and predictive factors (e.g., disease-free 
interval); carcinoembryonic antigen, lactate dehydrogenase and alkaline phosphatase level at 
baseline (pre-chemotherapy or pre-thoracotomy); number and distribution of lung metastases; date 
of surgical intervention; chemotherapy history; date of first progression; and date of death or last 
follow-up visit. When exceeding 25 the number of lung metastases was put into the database with 
the absolute value of 30 and described in the results as “>25”. 
Three subgroups of patients were identified : group 1 (G1) including patients with at least one organ 
involved other than the lung; group 2 (G2) including patients with lung metastases as the sole site of 
advanced disease and not submitted to lung surgery; group 3 (G3) patients with lung metastases as 
the sole site of advanced disease and submitted to lung surgery (Figure 1). 
 
Outcome evaluation 
Response evaluation was performed under the standard assessment criteria used at each institution 
for the considered timeframe. Up to 2001, treatment response was classified according to 
International Union Against Cancer (UICC) criteria (14), wherein complete response was defined as 
the complete disappearance of all clinically detectable malignant disease, partial response as a 
decrease 50% in the sum of the products of the two longest perpendicular diameters of all 
measurable lesions, and progressive disease as an increase of at least 25% in the size of measurable 
lesions and the development of new lesions. After 2001, centers were invited to classify responses 
according to the RECIST criteria (15), wherein response was defined as a decrease >30% in the 
sum of the longest diameters of target lesions, and a progressive disease as an increase >20% of this 
sum. Only the best tumor response was recorded. 
Progression-free survival and overall survival were estimated from first-line treatment onset till 
progression or death from any cause or date of the last follow-up. The cut-off date for the collection 
of data was January 31
st
, 2011. Patients not progressing or alive or lost to follow-up at the time of 
the cut-off date were censored at the time of the last follow-up examination. 
 
Surgical criteria 
All patients with lung metastases were considered for lung resection  at two thoracic surgery 
centers, one located at University of Torino, San Luigi Gonzaga Hospital (also referral center for
 
the 
Oncology Unit at IRCC Candiolo) and the second one at University of Eastern Piedmont, Maggiore 
della Carità Hospital, Novara. While each institution evaluated patient eligibility for lung resection 
according to its own internal diagnostic work up procedures and by a multidisciplinary team which 
included the thoracic surgeon, the mandatory criteria requested for the inclusion in this retrospective 
study were: resection with curative intent and with a predicted adequate residual pulmonary reserve 
after surgery in the absence of unresectable non-pulmonary localization. Surgery was performed 
upfront when resectability criteria were met. A surgical re-evaluation was planned in case of tumor 
response or stabilization after chemotherapy. 
 
Statistical analyses 
Differences between proportions were evaluated using the chi-square test with Yates correction, 
when necessary. Differences between groups of non parametric unpaired variables were validated 
by the Mann-Whitney U test when comparing two groups or the Kruskal-Wallis Analysis of 
Variance when analyzing multiple groups. Logistic regression analysis was performed to eliminate 
confounding parameters when examining dichotomous variables. Survival curves were plotted 
using the Kaplan-Meier method and validated using the log-rank test. Multivariate survival analysis 
was performed according to the Cox proportional-hazards model. All statistical computations were 
performed using SPSS for Windows Ver 16.0 and STATISTICA for Windows Ver. 6.0 software. 
 
RESULTS 
Patient characteristics 
Data from 1411 CRC patients (Table 1) were retrospectively considered, 409 of which presented 
with lung metastases and composed the primary dataset for the present analyses. Patients were 
grouped as follows: G1 composed of patients with lung and extra-pulmonary metastases (n= 255); 
G2 composed of patients with the lung as the sole metastatic site and not submitted to lung 
resection (n=104); G3 included patients submitted to resection (n=50) (Figure 1). Surgery was 
performed after neoadjuvant chemotherapy in 19 out of 50 patients. Table 2 summarizes the 
characteristics of the 409 patients included in the study. 
The three groups were comparable for gender, Eastern Cooperative Oncology Group (ECOG) 
performance status, and circulating serum prognostic factors such as lactate dehydrogenase (LDH), 
carcinoembrionic antigen (CEA) and alkaline phosphatase (ALP). There was an expectedly higher 
proportion of colon cancers in group 1 than in the other two groups but no difference was observed 
between G2 and G3. Patient age and tumor stage at diagnosis were fairly similar in G1 and G2. The 
median age was significantly lower in G3 than in group 2 (60.8 and 65.9 years, respectively; p 
<0.004) and there was a higher proportion of metachronous tumors in G3 than in G2 (88% and 
56.7%, respectively; X
2
 p <0.0001). Median disease free interval was higher in G3 than in G2 and 
G1 (23.7, 5, and 0.5 months, respectively. ANOVA p<0.001).  
 
Chemotherapy and lung surgery 
A total of 371/409 (98.1%) patients received chemotherapy as first-line treatment; 7/409 were not 
treated because of poor performance status (n=2), concomitant invalidating diseases (n=2), and 
unknown reasons (n=3). Thirty-one patients in G3 received lung surgery upfront and were not 
subsequently evaluable for chemotherapy response. The choice about systemic chemotherapy was 
left to each investigator center discretion. The majority of patients (262/371, 70.6%) received an 
oxaliplatin-containing doublet, 51/371 (13.8%) received an irinotecan-based chemotherapy, and 56 
(15.1%) a fluoropyrimidine-based chemotherapy. Two patients received a triplet. Nineteen patients 
in G2 (18.5%) received a single agent fluoropyrimidine chemotherapy as they were considered unfit 
(older patients or those with other comorbidities), and one patient in G3 received a triplet. No more 
difference in the type of chemotherapy administered between G2 and G3 was found (Table 2). The 
overall response rate was 38.0% (141/371 patients): 36.1% (90/249) in G1; 35.9% (37/103) in G2; 
and 73.7% (14/19) in G3, respectively. There was no difference between the three groups. All 31 
patients submitted to pulmonary resection upfront received chemotherapy within 2 months of 
surgery. Most received 12 cycles of FOLFOX; only 3 received 12 courses of FOLFIRI. 
The median number of lung metastases (range) was 5 (1->25), 5 (1-15), and 1 (1-6) in G1, G2, and 
G3, respectively (ANOVA p<0.001). A higher proportion of unilateral distribution was recorded in 
G3 (64%) than in G2 (37.5%) or in G1 (37.6%) (X
2
 p=0.01). Resection was performed in 50/154 
(32.5%) patients (31 upfront and 19 after neoadjuvant chemotherapy) with only metastatic lung 
disease. Reasons for surgery delay were: primary tumor not deemed controlled in 12 patients, and 
complete resection not considered technically possible in 7 patients. Wedge resection was 
performed in 34 (68%) patients, lobectomy in 10 (20%), segmentectomy in 5 (10%), and 
bilobectomy in 1 patient (2%). No postoperative mortality or major complications were reported. 
Resection was complete (R0) in 49/50 patients. In only one patient residual tumor was 
microscopically documented in the surgical margins. One other patient underwent a second 
complete lung resection 1 month after the first surgical treatment. 
Twenty-one patients in G2 who present resectable disease, surgery was not performed due to lung 
disease or other health conditions (mainly poor lung function reserve or cardiac disease). Eight 
patients in G1 with liver and lung metastases were submitted to liver and then to lung resection. 
The proportion of patients submitted to lung resection was higher in those centers with in house 
thoracic surgery facilities: 21/53 (39.6%) in center 1; 15/32 (46.9%) in center 3; 14/69 (20.3%) in 
center 2 (center 1 vs. center 2, X
2
 p=0.01). However, there was no difference between centers in the 
proportion of patients with 6 or less lung metastases (the upper range of G3) not submitted to 
surgery (i.e. patients in G2), nor in their distribution (ANOVA p>0.5 for both analyses).  
 
 
Clinical outcomes 
At the time of data computation (January 31
st
 2011), 334/409 (81.7%) patients had progressed. The 
median progression-free survival of the entire population was 11.3 months. Figure 2 reports the 
progression-free survival curves for each group. The median duration of progression-free survival 
(95%CI) was 10.3 (9.4-11.2) months in G1, 10.5 (9.6-11.4) months in G2, and 26.2 (10.4-42) 
months in G3 (p <0.001). While the duration of progression-free survival was similar for the 
patients with lung metastases as the sole site of disease not submitted to resection (G2) and those 
with lung and extra-pulmonary metastases (G1) (10.5 vs. 10.3 months; p=ns; HR 1.09, 95%CI 0.96-
1.22), it was longer in the resected patients (G3) than in those with the lung as the sole metastatic 
site and not submitted to surgery (G2) (26.2 vs. 10.5 months; p <0.0001; HR 0.24, 95%CI 0.01-
0.47). In the 19 patients who had received neo-adjuvant chemotherapy before surgery, the median 
duration of progression-free survival was 26.4 months, comparable to that of the patients 
undergoing upfront surgery (26.2 months). 
At the cut-off date of data collection (January 31
st
 2011), the overall median survival of the entire 
population was 29.4 months. Figure 3 reports the Kaplan-Meier estimated curves for each group. 
The median duration of overall survival (95%CI) was: 24.2 (21.5-26.9) months (G1); 31.5 (28.8-
34.2) months (G2); and 72.4+ (40.7-104.1) months (G3), respectively (p <0.001). Survival was 
longer in those patients with the lung as the sole metastatic site as compared to those with 
pulmonary and extra-pulmonary metastatic sites (31.5 vs. 24.2 months; p <0.03, HR 0.76, 95%CI 
0.62-0.90). Patients who had undergone surgical resection of pulmonary metastases (G3) survived 
strikingly longer than those who had not (G2) (72.4+ vs. 31.5 months; p<0.0001; HR 0.17, 95%CI 
0.01-0.33). No statistically validated difference in overall survival emerged between patients 
submitted or not to neoadjuvant chemotherapy (70.1+ vs 72.4+ months; p=0.9). 
At the cut-off date of data collection, 14/50 resected patients (G3) (28%) had died. The remaining 
36 patients still alive were followed for a median of 41.3 months (range, 4.0-134.1). Seventeen 
(34%) were alive for more than 5 years (five of them without sign of disease) and 3 (6%) for more 
than 10 years (two disease-free) after diagnosis of advanced CRC, whereas only 4 (4.8%) of those 
patients in group 2 (patients with lung metastases not submitted to resection) were alive after 5 
years (all with progressive disease).  
 
Multivariate analyses 
Logistic regression analysis for surgery (value=1) vs no surgery (value=0) stratified for center 
confirmed age (HR; 95%CI: 0.96; 0.94-0.98), disease free interval (1.03; 1.02-1.04), ECOG 
performance status (0.54; 0.17-0.91), and the number of lung metastases (0.70; 0.62-0.70) as 
independent factors. Date of surgery, gender, tumor grade, CEA, LDH, ALP, distribution of lung 
metastases, and site of the primary did not enter the model. 
In order to eliminate confounding variables, multivariate Cox analyses for predictors of 
progression-free survival and overall survival were performed in the entire population of 1411 
patients with metastatic disease (Table 3 and 4). 
Rectal localization, disease-free interval (as a continuous variable), hemoglobin level >12 g/dl, 
ECOG performance status, and surgery of liver and lung metastases were found to be independent 
factors for progression-free survival (Table 3). Age, treatment center, tumor stage at diagnosis, 
grading, gender, and number of metastatic sites did not enter the model. 
Disease-free interval (as a continuous variable), the presence of liver metastases, hemoglobin level 
>12 g/dl, number of metastatic sites, and surgery of liver and lung metastases were found to be 
independent factors of overall survival (Table 4). Age, treatment center, tumor stage at diagnosis, 
grading, gender, ECOG performance status, and rectal localization did not enter the model. 
 
DISCUSSION 
In this large retrospective study in metastatic CRC patients we observed a remarkably longer 
duration of progression-free survival and overall survival in patients submitted to resection with 
radical intent of their pulmonary metastases compared to those who received chemotherapy alone. 
This is the first study to compare outcomes in the same series of patients and not against historical 
reports.  
The incidence of synchronous lung metastases was higher in our study population than that 
previously reported (16): 29% of patients presented synchronous lung metastases and 10.9% had 
only lung localizations. This may be explained in part by the fact that the staging procedure 
included thoracic computed tomography (CT), which has been demonstrated to be more sensitive 
than conventional X-ray (17). Nearly one third of the patients (50/154) with the lung as the sole 
metastatic site underwent surgery. This number does not include the 8 patients submitted to liver 
and subsequently to pulmonary resection, as they were included in  G1 (patients with lung and 
extra-pulmonary metastases) in an intention to treat analysis.  
Not surprisingly, patients submitted to surgery were, on average, younger. The incidence of chronic 
lung diseases such as chronic obstructive pulmonary disease increases with age. As a consequence 
of these chronic comorbilities, older subjects more frequently have poor lung function reserve and 
are ineligible for surgery, as it was the case for 21 patients in this study. This might represent a 
selection bias, as younger patients are assumed to have a longer duration of survival, even if other 
series have not shown this difference (18), or even reported an opposite pattern (19). 
Quite unexpectedly, a higher number of tumors with metachronous lung metastases was observed in 
the resected subgroup. Synchronous metastases of CRC are considered to carry a worse prognostic 
value compared with metachronous metastases, but there are few and conflicting reported data. A 
large retrospective study from the CAIRO study of the Dutch Colorectal Cancer Group (DCCG) 
concluded that, despite unfavorable clinical-pathological features in patients with synchronous 
metastases, no difference in the median duration of overall survival was observed (20). A possible 
explanation could be the relative chemoresistance of metachronous metastases due to adjuvant 
treatments. In our study, 31/42 (73.8%) patients in G3 and 34/59 (57.6%) patients in G2 received 
adjuvant chemotherapy. Although not statistically validated, this difference is worth of 
consideration. 
As demonstrated by the logistic regression analysis, age, disease free interval and the number of 
metastases are the variables that drove surgeons through the decision process. Even though 
discrepant results have been reported in literature on the possible prognostic role of these three 
variables, it is reasonable to think that resected patients were those destined to have per se a longer 
survival as they were younger, presented with a longer disease free interval and a lower number of 
lung metastases than those not submitted to surgery. 
One open question concerns whether the strikingly longer survival of patients submitted to lung 
resection is due to the beneficial effect of surgery itself or to the selection bias above described (21, 
22). There is a large body of literature reporting survival benefits gained from lung resection (5-7, 
18-22). However, a sort of citation cascade of the same few studies reporting these survival benefits 
excluding those with negative results might have resulted in an unfounded “authority of claim” as 
recently demonstrated by Fiorentino et al. (8). Optimally this question could be definitively 
answered by a phase III trial (13). However, if it could be indirectly demonstrated that surgery is 
effectively beneficial in curing patients or at least prolonging survival, such a comparative trial 
would have lower priority from a medical oncology point of view; such was the case for surgery for 
the treatment of liver metastasis. 
Our data confirm a better outcome in those patients submitted to surgery than in those treated with 
chemotherapy alone in the same institutions and during the same period of time. In the resected 
subgroup, 17 patients are alive after more than 5 years and 3 more than 10 years after the diagnosis 
of advanced cancer, whereas only 4 of those in G2 are alive after 5 years. Interestingly, of the 8 
patients in G1 submitted to liver and subsequently lung resection, the duration of survival was 5 
years in 2 patients and 10 years in 1 patient.  
Several published studies have discussed the importance of finding surrogate end points as outcome 
indicators. Response rate and progression-free survival after first-line treatment have been proposed 
and validated in CRC patients (23-25) as their evaluation allows a reliable quantitative estimate of 
the efficacy of new drugs or new techniques with a lower degree of potential bias. In our 
retrospective study, patients were treated with chemotherapy (G1 and 2) or with surgery. Response 
to first-line treatment was similar in G1 and G2 (36.1 and 35.9%, respectively). Determining 
treatment response in G3 patients was difficult because 31 patients received surgery before 
chemotherapy: if we take into account only the 19 patients who received chemotherapy before 
surgery, the response rate was 73.7%; if we consider, however, surgery as an active first-line 
treatment, the response rate of the whole group was 98%, as residual tumor after surgery (R1) was 
evident in only 1 patient. Patients submitted to surgery presented a median duration of progression-
free survival of 26.2 months, more than twice that recorded in those not resected (10.5 months). 
Interestingly, the duration of progression-free survival was similar for G1 and G2 (10.3 months). At 
multivariate analyses of the complete patient dataset of 1411 subjects, liver and lung surgery 
emerged as independent factors for both progression-free and overall survival. These findings 
further suggest that surgery is a more active treatment than chemotherapy alone. 
 
In conclusion, the results of our retrospective study provide evidence suggesting that surgery is a 
more active treatment than chemotherapy alone when performed as first-line treatment. Although 
resectable patients are probably those destined to have a more indolent form of the disease as they 
have theoretically favorable prognostic factors, surgery can further improve their outcome. In our 
study we recorded 10-year survivors only in G3 and G1 (1 patient submitted to liver and then lung 
resection), but not in G2 in which some potentially resectable patients might have been included. 
Moreover, resected patients had a longer duration of progression-free survival, a validate surrogate 
end-point for clinical outcome. From a statistical point of view, our findings are insufficient to 
definitively solve the question of whether surgery is beneficial in resectable patients as this can be 
demonstrated only with a prospective randomized phase III trial. From a medical oncology point of 
view, however, our results add evidence to the debate whether such a study is still necessary. 
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 TABLE 1. Patient characteristics of the entire database of subjects followed and treated from the 
time of the first appearance of metastatic disease at three different institutions.  
 
  (%) 
No. of patients 1411  
Oncology centers    
San Luigi, Orbassano 601 42.6 
IRCC Candiolo 540 38.3 
Novara 270 19.1 
   
Median age (yrs) 
(range) 
63.2  
(26.8-87.4) 
 
   
Gender   
Male 848 60.1 
Female 563 39.9 
   
Site of primary tumor   
Colon 1040 73.7 
Rectum 371 26.3 
   
Stage at diagnosis   
A 6 0.4 
B 182 12.9 
C 389 27.6 
D 834 59.1 
   
ECOG performance status at chemotherapy 
onset 
  
0-1 887 62.9 
2 56 4.0 
3 9 0.6 
unknown 459 32.5 
   
Adjuvant Chemotherapy   
Stage B 94/182 51.6 
Stage C 297/389 76.3 
   
Distant Metastases   
No. of sites   
1 site 1073 76.0 
>1 site 338 24.0 
   
Sites involved   
Liver 975 69.1 
Lung 409 29.0 
Abdomen 318 22.5 
   
Surgery of metastases   
Liver 286 20.3 
Lung 58 4.1 
 
TABLE 2. Patient characteristics of the subjects enrolled into this study. Data are summarized as 
overall, group 1 (patients with lung and extra-pulmonary metastases), group 2 (patients with the 
lung as the only site of metastases not submitted to surgery), and group 3 (patients with the lung as 
the only site of metastases submitted to surgery). Data are expressed as number of patients (%). 
 
 Overall Group 1 Group 2 Group 3 
No. of patients 409 255 104 50 
     
Centers      
San Luigi, Orbassano 158 (38.6) 105 (41.2) 32 (30.8) 21 (42) 
IRCC Candiolo 148 (36.2) 79 (31.0) 55 (52.9) 14 (28) 
Novara 103 (25.2) 71 (27.8) 17 (16.3) 15 (30) 
     
     
Median age (yrs) 
(range) 
64.3  
(26.8-87.4) 
63.9 
(31.1-87.4) 
65.9 
(36.1-77.6) 
60.8 
(26.8-86.5) 
     
Gender:     
Male 241 (58.9) 147 (57.6) 62 (59.6) 32 (64) 
Female 168 (41.1) 108 (42.4) 42 (40.4) 18 (36) 
     
Site of primary tumor     
Colon 265 (64.8) 176 (69) 60 (57.7) 29 (58) 
Rectum 144 (35.2) 79 (31) 44 (42.3) 21 (42) 
     
Stage at diagnosis     
A 3 (0.7) 1 (0.3) 0 (0) 2 (4) 
B 58 (14.2) 26 (10.2) 17 (16.3) 15 (30) 
C 138 (33.7) 69 (27.1) 42 (40.4) 27 (54) 
D 210 (51.4) 159 (62.4) 45 (43.3) 6 (12) 
     
Adjuvant Chemotherapy     
Stage B 31/58 (53.4) 12/26 (46.2) 8/17 (47.1) 11/15 (73.3) 
Stage C 94/138 (68.1) 48/69 (70.0) 26/42 (61.9) 20/27 (74.1) 
     
Disease free interval 
median (5°-95° percentile) 
    
Months 1.37 (0-58.5) 0.5 (0-45.4) 5 (0-76.4) 23.7 (0-118.8) 
     
ECOG performance status 
at therapy onset 
    
0-1 314 (76.8) 195 (76.4) 77 (74) 42 (84) 
2 18 (4.4) 16 (6.3) 1 (1) 1 (2) 
3 2 (0.5) 1 (0.4) 1 (1) 0 (0) 
Unknown 75 (18.3) 43 (16.9) 25 (24) 7 (14) 
     
First-line chemotherapy     
Doublet with oxaliplatin 262/371 (70.6) 181/249 (72.7) 68/103 (66.0) 13/19 (68.4) 
Doublet with Irinotecan- 51/371 (13.8) 30/249 (12.0) 16/103 (15.5) 5/19 (26.3) 
Triplet 2/371 (0.5) 1/249 (0.4) 0/103 (0) 1/19 (5.3) 
5FU-based 56/371 (15.1) 37/249 (14.9) 19/103 (18.5) 0/19 (0) 
     
Clinical parameters at 
therapy onset$ 
    
LDH >240 U/L 175/235 (74.5) 122/156 (78.2) 29/44 (65.9) 24/35 (68.6) 
CEA >5 ng/ml 165/251 (65.7) 130/168 (77.4) 22/48 (45.8) 13/35 (37.1) 
ALP >120 U/L 140/236 (59.3) 110/156 (70.5) 15/45 (33.3) 15/35 (42.9) 
     
Distant metastases     
No. of sites      
1 site 154 (37.7) - - - 
>1 site 255 (62.3) - - - 
     
Sites      
Liver 227 (55.5) 227 (89) - - 
Lung 409 (100) 255 (100) - - 
Abdomen 68 (16.6) 68 (26.7) - - 
     
No. of lung metastases     
Median (range) 4 (1->25) 5 (1->25) 5 (1-15) 1 (1-6) 
     
Distribution of lung met     
Unilateral 167 (40.8) 96 (37.6) 39 (37.5) 32 (64.0) 
Bilateral 226 (55.3) 145 (56.9) 63 (60.6) 18 (36.0) 
Unknown 16 (3.9) 14 (5.5) 2 (1.9) 0 
$
Only for centers 1 and 3. LDH: lactate dehydrogenase (abnormal values >240 units/L); CEA: 
carcinoembryonic antigen (abnormal values >5 ng/mL); ALP: alkaline phosphatase (abnormal 
values >120 units/L). 
TABLE 3. Multivariate Cox proportional-hazards analyses of predictive factors in 1411 patients 
with colorectal cancer followed from the time of first appearance of metastatic disease. Progression-
free survival. 
 
Variable  HR 95% CI P value 
Rectal cancer  0.85 0.78-0.92 0.01 
Disease-free interval*  0.99 0.98-1.00 0.01 
Hemoglobin >12 g/dl  0.70 0.61-0.79 <0.001 
ECOG performance status  1.01 1.00-1.02 0.05 
Liver surgery  0.47 0.39-0.55 <0.0001 
Lung surgery  0.46 0.31-0.57 <0.0001 
CEA >5 ng/ml  1.48 1.37-1.59 <0.001 
CA 19-9 >37 U/l  1.22 1.12-1.32 0.03 
*Continuous variable. 
Age, center, tumor stage at diagnosis, grading, gender, number of metastatic sites, number of lung 
metastases, LDH and ALP levels, and the presence of liver metastases did not enter the model. 
 
 
 
 
 
TABLE 4. Multivariate Cox proportional-hazards analyses of predictive factors in 1411 patients 
with colorectal cancer followed from the time of first appearance of metastatic disease. Overall 
survival. 
 
Variable  HR 95% CI P value 
Liver metastases  1.42 1.33-1.51 <0.0001 
Hemoglobin >12 g/dl  0.72 0.62-0.82 <0.001 
ECOG performance status  1.01 1.00-1.02 0.10 
Liver surgery  0.26 0.16-0.36 <0.0001 
Lung surgery  0.26 0.06-0.46 <0.0001 
CEA >5 mg/ml  1.49 1.36-1.62 <0.001 
CA 19-9 >37 U/l  1.44 1.33-1.55 <0.001 
Age, center, tumor stage at diagnosis, grading, gender, number of metastatic sites, disease-free 
interval, LDH and ALP levels, and rectal cancer did not enter the model 
 
 
 
 
Figure Legend 
 
Figure 1. CONSORT diagram of the study. 
 
Figure 2. Kaplan-Meier estimate curves for progression-free survival according to patient subgroup 
(see text). A statistically significant longer survival was evident only in patients with lung 
metastases submitted to surgery (group 3). 
 
Figure 3. Kaplan-Meier estimate curves for overall survival according to patient subgroup (see text) 
. Differences were evident and validated between each group.  
Figure 1. 
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Group 1  255      122       40        24       16         9          6          5          3         1 
Group 2  104        55       11          5         2         0          0          0          0         0 
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